Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Inclusion Criteria: * Subjects with type 2 diabetes for more than 2 years * Subjects currently treated with unchanged insulin glargine dose (10 -100 units) for 2 weeks * Subjects currently treated with unchanged dose(s) for at least 1 month on one or two Oral Anti-diabetic drugs * BMI 25 - 40 kg/m2 * HbA1c \< 9.5 % Exclusion Criteria: * Known or suspected allergy to trial product(s) or related products * Previous randomisation in this trial * Pregnancy, breast-feeding, intention of becoming pregnant or pre-menopausal women judged not to be using adequate contraceptive measures (Only sterilisation, intra uterine devices and contraceptive pills are considered adequate contraceptive methods) * Mental incapacity, unwillingness or language barriers precluding adequate understanding and co-operation. * Any other significant illness such as endocrine, cardiac, neurological, malignant or other pancreatic illness judged by Investigator * Participation in other studies within the last three months